OMNIBUS AMENDMENTEditas Medicine, Inc. • February 26th, 2021 • Biological products, (no disgnostic substances) • Massachusetts
This Omnibus Amendment (the “Amendment”) is entered into as of January 11, 2021 (the “Amendment Effective Date”), by and between The Broad Institute, Inc., a non-profit Massachusetts corporation, with a principal office at 415 Maine Street, Cambridge, MA 02142 (“Broad”) and Editas Medicine, Inc., a Delaware corporation, located at 11 Hurley Street, Cambridge, MA 02141 (“Editas”), and amends (i) that certain Cpf1 License Agreement, dated as of December 16, 2016 (the “Cpf1 Agreement”) and (ii) that certain Cas9-II License Agreement, dated as of December 16, 2016 (the “Cas9-II Agreement” and together with the Cpf1 Agreement, the “Agreements”). Broad and Editas may be referred to herein individually as a “Party” and collectively as the “Parties.”
VIA ELECTRONIC MAIL February 4, 2021 (revised) Cynthia Collins Dear Cindy:Editas Medicine, Inc. • February 26th, 2021 • Biological products, (no disgnostic substances) • Massachusetts
As we discussed, your employment with Editas Medicine, Inc. (the “Company”) will end effective February 15, 2021 (the “Separation Date”). As we also discussed, you will be eligible to receive the severance benefits described in paragraph 1 below if you sign and return this letter agreement to me by February 26, 2021 (but no earlier than the Separation Date) and do not revoke your agreement (as described below). By signing and returning this letter agreement and not revoking your acceptance, you will be entering into a binding agreement with the Company and will be agreeing to the terms and conditions set forth in the numbered paragraphs below, including the release of claims set forth in paragraph 2. Therefore, you are advised to consult with an attorney before signing this letter agreement and you have been given at least twenty-one (21) days to do so. If you sign this letter agreement, you may change your mind and revoke your agreement during the seven (7) business day period after y
FIRST AMENDMENT TO SPONSORED RESEARCH AGREEMENTSponsored Research Agreement • February 26th, 2021 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Amendment (the “SRA Amendment”) is entered into as of January 11, 2021 (the “SRA Amendment Effective Date”), by and between The Broad Institute, Inc., a non-profit Massachusetts corporation, with a principal office at 415 Maine Street, Cambridge, MA 02142 (“Broad”) and Editas Medicine, Inc., a Delaware corporation, located at 11 Hurley Street, Cambridge, MA 02141 (“Editas”), and amends that certain Sponsored Research Agreement, dated as of June 7, 2018 (the “Sponsored Research Agreement”). Broad and Editas may be referred to herein individually as a “Party” and collectively as the “Parties.”
